Author:
Lozenski Karissa,Ownbey Robert,Wigdahl Brian,Kish-Catalone Tina,Krebs Fred C
Abstract
Abstract
Background
The disappointing clinical failures of five topical vaginal microbicides have provided new insights into factors that impact microbicide safety and efficacy. Specifically, the greater risk for human immunodeficiency virus type 1 (HIV-1) acquisition associated with multiple uses of a nonoxynol-9 (N-9)-containing product has highlighted the importance of application frequency as a variable during pre-clinical microbicide development, particularly in animal model studies.
Methods
To evaluate an association between application frequency and N-9 toxicity, experiments were performed using a mouse model of cervicovaginal microbicide safety. In this model system, changes in cervical and vaginal epithelial integrity, cytokine release, and immune cell infiltration were assessed after single and multiple exposures to N-9.
Results
After the initial application of N-9 (aqueous, 1%), considerable damage to the cervical epithelium (but not the vaginal epithelium) was observed as early as 10 min post-exposure and up to 8 h post-exposure. Subsequent daily exposures (up to 4 days) were characterized by diminished cervical toxicity relative to single exposures of like duration. Levels of pro-inflammatory cytokines released into the cervicovaginal lumen and the degree of CD14-positive immune cell infiltration proximal to the cervical epithelium were also dependent on the number of N-9 exposures.
Conclusions
Rather than causing cumulative cervical epithelial damage, repeated applications of N-9 were characterized by decreased sensitivity to N-9-associated toxicity and lower levels of immune cell recruitment. These results provide new insights into the failure of N-9-based microbicides and illustrate the importance of considering multiple exposure protocols in pre-clinical microbicide development strategies.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference44 articles.
1. Global Report: UNAIDS report on the global AIDS epidemic 2010.http://www.unaids.org/globalreport/Global_report.htm,
2. Ramjee G: Microbicide research: current and future directions. Curr Opin HIV AIDS. 2010, 5 (4): 316-321. 10.1097/COH.0b013e32833a9f66.
3. Nuttall J: Microbicides in the prevention of HIV infection: current status and future directions. Drugs. 2010, 70 (10): 1231-1243.
4. Minces LR, McGowan I: Advances in the Development of Microbicides for the Prevention of HIV Infection. Curr Infect Dis Rep. 2010, 12 (1): 56-62. 10.1007/s11908-009-0076-5.
5. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002, 360 (9338): 971-977. 10.1016/S0140-6736(02)11079-8.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献